DOI: 10.1016/j.urolonc.2007.03.015. Nanoparticles for drug delivery in cancer treatment

Nanoparticles for drug delivery in cancer treatment

10.1016/j.urolonc.2007.03.015

Crossref journal-article

Elsevier BV

Urologic Oncology: Seminars and Original Investigations (78)

Bibliography

Haley, B., & Frenkel, E. (2008). Nanoparticles for drug delivery in cancer treatment. Urologic Oncology: Seminars and Original Investigations, 26(1), 57â64.

Authors 2

Barbara Haley (first)
Eugene Frenkel (additional)

References 48 Referenced 564

{'key': '10.1016/j.urolonc.2007.03.015_bib1', 'first-page': '209', 'article-title': 'New developments in angiogenesis: A major mechanism for tumor growth and target for therapy', 'volume': '4', 'author': 'Jones', 'year': '1998', 'journal-title': 'Cancer J Sci Am'} / Cancer J Sci Am / New developments in angiogenesis: A major mechanism for tumor growth and target for therapy by Jones (1998)
10.1016/S0169-409X(98)00003-9 / Adv Drug Deliv Rev / Control of tumor vascular permeability by Baban (1998)
10.1073/pnas.95.8.4607 / Proc Natl Acad Sci USA / Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment by Hobbs (1998)
10.1016/S0009-9260(66)80027-2 / Clin Radiol / Microcirculation of tumors by Rubin (1966)
10.1007/BF00409698 / J Cancer Res Clin Oncol / Vascularization of tumors: A review by Shubik (1982)
10.1016/S0169-409X(00)00131-9 / Adv Drug Deliv Rev / Delivery of molecular and cellular medicine to solid tumors by Jain (2001)
10.1023/A:1025785505977 / Pharm Res / Drug delivery and transport to solid tumors by Jang (2003)
10.1016/S0065-2571(00)00013-3 / Adv Enzyme Regul / The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting by Maeda (2001)
10.1016/S0168-3659(99)00248-5 / J Control Release / Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review by Maeda (2000)
10.1016/S0928-0987(00)00114-7 / Eur J Pharm Sci / Multidrug resistance (MDR) in cancer by Krishna (2000)
{'key': '10.1016/j.urolonc.2007.03.015_bib11', 'first-page': '1', 'article-title': 'Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs', 'author': 'Links', 'year': '1999', 'journal-title': 'Expert Rev Mol Med'} / Expert Rev Mol Med / Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs by Links (1999)
10.1023/A:1026732405381 / Histochem J / Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells by Calcabrini (2000)
10.1177/153303460500400405 / Technol Cancer Res Treat / Targeted drug delivery in cancer therapy by Vasir (2005)
10.1016/0169-409X(95)00039-A / Adv Drug Deliv Rev / Surface modification of nanoparticles to oppose uptake by the mononuclear phagocytic system by Storm (1995)
10.1016/S0169-409X(02)00044-3 / Adv Drug Deliv Rev / Nanoparticles in cancer therapy and diagnosis by Brigger (2002)
10.1016/0021-9797(91)90043-8 / J Colloid Interface Sci / Protein-surface interactions in the presence of polyethylene oxide by Jeon (1991)
10.1016/S1470-2045(06)70793-8 / Lancet Oncol / Emerging use of nanoparticles in diagnosis and treatment of breast cancer by Yezhelyev (2006)
10.1016/S1053-4296(98)80042-8 / Semin Radiat Oncol / Transvascular drug delivery in solid tumors by Yuan (1998)
10.1158/0008-5472.CAN-04-3921 / Cancer Res / Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer by Kukowska-Latallo (2005)
10.1016/S0169-409X(99)00062-9 / Adv Drug Deliv Rev / Targeted drug delivery via the folate receptor by Sudimack (2000)
10.1016/S0142-9612(99)00125-8 / Biomaterials / Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkyl cyanoacrylate nanoparticles by Soma (2000)
10.1016/j.nano.2004.11.009 / Nanomed Nanotech Biol Med / Nanostructure-mediated drug delivery by Hughes (2005)
10.1096/fj.04-2747rev / FASEB J / Nanomedicine: Current status and future prospects by Moghimi (2005)
10.1038/380561a0 / Nature / Doxorubicin in sterically stabilized liposomes by Lasic (1996)
10.1126/science.7434025 / Science / pH-sensitive liposomes: Possible clinical implications by Yalvin (1980)
{'key': '10.1016/j.urolonc.2007.03.015_bib26', 'first-page': '2186', 'article-title': 'Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes', 'volume': '54', 'author': 'Huang', 'year': '1994', 'journal-title': 'Cancer Res'} / Cancer Res / Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes by Huang (1994)
10.1093/annonc/mdh097 / Ann Oncol / Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) vs. conventional doxorubicin for first-line treatment of metastatic breast cancer by O’Brien (2004)
10.1016/S0022-3565(24)38244-8 / J Pharmacol Exp Ther / Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes by Working (1999)
{'key': '10.1016/j.urolonc.2007.03.015_bib29', 'first-page': '22', 'article-title': 'Stealth Liposomes', 'author': 'Lasic', 'year': '1995'} / Stealth Liposomes by Lasic (1995)
10.1200/JCO.2001.19.14.3312 / J Clin Oncol / Recurrent epithelial ovarian carcinoma: A randomized Phase III study of pegylated liposomal doxorubicin vs. topotecan by Gordon (2001)
10.1200/JCO.1998.16.7.2445 / J Clin Oncol / Pegylated-liposomal doxorubicin vs. doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: Results of a randomized Phase III clinical trial by Northfelt (1998)
10.1200/JCO.1998.16.2.683 / J Clin Oncol / Randomized comparative trial of pegylated liposomal doxorubicin vs. bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma by Stewart (1998)
10.1097/01.cad.0000167902.53039.5a / Anticancer Drugs / Liposomal encapsulated anti-cancer drugs by Hofheinz (2005)
10.1200/JCO.1996.14.8.2353 / J Clin Oncol / Randomized Phase III trial of liposomal daunorubicin vs. doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma by Gill (1996)
{'key': '10.1016/j.urolonc.2007.03.015_bib35', 'series-title': 'San Antonio Breast Cancer Symposium', 'article-title': 'Increased endothelial transcytosis of nanoparticle albumin-bound paclitaxel (AB1-007) by endothelial gp60 receptors: A pathway inhibited by Taxol', 'author': 'Desai', 'year': '2004'} / San Antonio Breast Cancer Symposium / Increased endothelial transcytosis of nanoparticle albumin-bound paclitaxel (AB1-007) by endothelial gp60 receptors: A pathway inhibited by Taxol by Desai (2004)
10.1046/j.1432-1327.2001.02107.x / Eur J Biochem / High affinity binding of paclitaxel to human serum albumin by Paal (2001)
10.1016/S0167-4838(99)00251-4 / Biochim Biophys Acta / Interaction of taxol with human serum albumin by Purcell (2000)
{'key': '10.1016/j.urolonc.2007.03.015_bib38', 'first-page': '1027', 'article-title': 'The differential expression of SPARC in esophageal squamous cell carcinoma', 'volume': '17', 'author': 'Che', 'year': '2006', 'journal-title': 'Int J Mol Med'} / Int J Mol Med / The differential expression of SPARC in esophageal squamous cell carcinoma by Che (2006)
{'key': '10.1016/j.urolonc.2007.03.015_bib39', 'first-page': '5376', 'article-title': 'Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients', 'volume': '63', 'author': 'Koukourakis', 'year': '2003', 'journal-title': 'Cancer Res'} / Cancer Res / Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients by Koukourakis (2003)
10.1158/1078-0432.CCR-05-1634 / Clin Cancer Res / Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel by Desai (2006)
{'year': '2005', 'series-title': 'Abraxane prescribing information', 'key': '10.1016/j.urolonc.2007.03.015_bib41'} / Abraxane prescribing information (2005)
10.1200/JCO.2005.04.937 / J Clin Oncol / Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer by Gradishar (2005)
{'key': '10.1016/j.urolonc.2007.03.015_bib43', 'series-title': 'San Antonio Breast Cancer Symposium', 'article-title': 'Weekly nanoparticle albumin paclitaxel (Abraxane) results in long term disease control in patients with taxane-refractory metastatic breast cancer', 'author': 'O’Shaughnessy', 'year': '2000'} / San Antonio Breast Cancer Symposium / Weekly nanoparticle albumin paclitaxel (Abraxane) results in long term disease control in patients with taxane-refractory metastatic breast cancer by O’Shaughnessy (2000)
10.1056/NEJMoa041318 / N Engl J Med / Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer by Petrylak (2004)
10.1056/NEJMoa040720 / N Engl J Med / Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer by Tannock (2004)
10.1073/pnas.0601755103 / Proc Natl Acad Sci USA / Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo by Farokhzad (2006)
10.1002/ijc.20405 / Int J Cancer / Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer by Sahoo (2004)
10.2174/1567201054368002 / Curr Drug Deliv / Folate-linked lipid-based nanoparticle for targeted gene delivery by Hattori (2005)

Dates

Type	When
Created	17 years, 7 months ago (Jan. 10, 2008, 9:12 a.m.)
Deposited	7 months, 1 week ago (Jan. 25, 2025, 9:25 a.m.)
Indexed	5 days, 15 hours ago (Aug. 31, 2025, 6:16 a.m.)
Issued	17 years, 8 months ago (Jan. 1, 2008)
Published	17 years, 8 months ago (Jan. 1, 2008)
Published Print	17 years, 8 months ago (Jan. 1, 2008)

Funders 0

None

BibTeX

@article{Haley_2008, title={Nanoparticles for drug delivery in cancer treatment}, volume={26}, ISSN={1078-1439}, url={http://dx.doi.org/10.1016/j.urolonc.2007.03.015}, DOI={10.1016/j.urolonc.2007.03.015}, number={1}, journal={Urologic Oncology: Seminars and Original Investigations}, publisher={Elsevier BV}, author={Haley, Barbara and Frenkel, Eugene}, year={2008}, month=jan, pages={57–64} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        8,
        31
      ]
    ],
    "date-time": "2025-08-31T10:16:54Z",
    "timestamp": 1756635414289,
    "version": "3.33.0"
  },
  "reference-count": 48,
  "publisher": "Elsevier BV",
  "issue": "1",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2008,
            1,
            1
          ]
        ],
        "date-time": "2008-01-01T00:00:00Z",
        "timestamp": 1199145600000
      },
      "content-version": "tdm",
      "delay-in-days": 0,
      "URL": "https://www.elsevier.com/tdm/userlicense/1.0/"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2008,
        1
      ]
    ]
  },
  "DOI": "10.1016/j.urolonc.2007.03.015",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2008,
        1,
        10
      ]
    ],
    "date-time": "2008-01-10T14:12:22Z",
    "timestamp": 1199974342000
  },
  "page": "57-64",
  "source": "Crossref",
  "is-referenced-by-count": 564,
  "title": "Nanoparticles for drug delivery in cancer treatment",
  "prefix": "10.1016",
  "volume": "26",
  "author": [
    {
      "given": "Barbara",
      "family": "Haley",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "Eugene",
      "family": "Frenkel",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "78",
  "reference": [
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib1",
      "first-page": "209",
      "article-title": "New developments in angiogenesis: A major mechanism for tumor growth and target for therapy",
      "volume": "4",
      "author": "Jones",
      "year": "1998",
      "journal-title": "Cancer J Sci Am"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib2",
      "doi-asserted-by": "crossref",
      "first-page": "109",
      "DOI": "10.1016/S0169-409X(98)00003-9",
      "article-title": "Control of tumor vascular permeability",
      "volume": "34",
      "author": "Baban",
      "year": "1998",
      "journal-title": "Adv Drug Deliv Rev"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib3",
      "doi-asserted-by": "crossref",
      "first-page": "4607",
      "DOI": "10.1073/pnas.95.8.4607",
      "article-title": "Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment",
      "volume": "95",
      "author": "Hobbs",
      "year": "1998",
      "journal-title": "Proc Natl Acad Sci USA"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib4",
      "doi-asserted-by": "crossref",
      "first-page": "220",
      "DOI": "10.1016/S0009-9260(66)80027-2",
      "article-title": "Microcirculation of tumors",
      "volume": "17",
      "author": "Rubin",
      "year": "1966",
      "journal-title": "Clin Radiol"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib5",
      "doi-asserted-by": "crossref",
      "first-page": "211",
      "DOI": "10.1007/BF00409698",
      "article-title": "Vascularization of tumors: A review",
      "volume": "103",
      "author": "Shubik",
      "year": "1982",
      "journal-title": "J Cancer Res Clin Oncol"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib6",
      "doi-asserted-by": "crossref",
      "first-page": "149",
      "DOI": "10.1016/S0169-409X(00)00131-9",
      "article-title": "Delivery of molecular and cellular medicine to solid tumors",
      "volume": "46",
      "author": "Jain",
      "year": "2001",
      "journal-title": "Adv Drug Deliv Rev"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib7",
      "doi-asserted-by": "crossref",
      "first-page": "1337",
      "DOI": "10.1023/A:1025785505977",
      "article-title": "Drug delivery and transport to solid tumors",
      "volume": "20",
      "author": "Jang",
      "year": "2003",
      "journal-title": "Pharm Res"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib8",
      "doi-asserted-by": "crossref",
      "first-page": "189",
      "DOI": "10.1016/S0065-2571(00)00013-3",
      "article-title": "The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting",
      "volume": "41",
      "author": "Maeda",
      "year": "2001",
      "journal-title": "Adv Enzyme Regul"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib9",
      "doi-asserted-by": "crossref",
      "first-page": "271",
      "DOI": "10.1016/S0168-3659(99)00248-5",
      "article-title": "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review",
      "volume": "65",
      "author": "Maeda",
      "year": "2000",
      "journal-title": "J Control Release"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib10",
      "doi-asserted-by": "crossref",
      "first-page": "265",
      "DOI": "10.1016/S0928-0987(00)00114-7",
      "article-title": "Multidrug resistance (MDR) in cancer",
      "volume": "11",
      "author": "Krishna",
      "year": "2000",
      "journal-title": "Eur J Pharm Sci"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib11",
      "first-page": "1",
      "article-title": "Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs",
      "author": "Links",
      "year": "1999",
      "journal-title": "Expert Rev Mol Med"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib12",
      "doi-asserted-by": "crossref",
      "first-page": "599",
      "DOI": "10.1023/A:1026732405381",
      "article-title": "Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells",
      "volume": "32",
      "author": "Calcabrini",
      "year": "2000",
      "journal-title": "Histochem J"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib13",
      "doi-asserted-by": "crossref",
      "first-page": "363",
      "DOI": "10.1177/153303460500400405",
      "article-title": "Targeted drug delivery in cancer therapy",
      "volume": "4",
      "author": "Vasir",
      "year": "2005",
      "journal-title": "Technol Cancer Res Treat"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib14",
      "doi-asserted-by": "crossref",
      "first-page": "31",
      "DOI": "10.1016/0169-409X(95)00039-A",
      "article-title": "Surface modification of nanoparticles to oppose uptake by the mononuclear phagocytic system",
      "volume": "17",
      "author": "Storm",
      "year": "1995",
      "journal-title": "Adv Drug Deliv Rev"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib15",
      "doi-asserted-by": "crossref",
      "first-page": "631",
      "DOI": "10.1016/S0169-409X(02)00044-3",
      "article-title": "Nanoparticles in cancer therapy and diagnosis",
      "volume": "54",
      "author": "Brigger",
      "year": "2002",
      "journal-title": "Adv Drug Deliv Rev"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib16",
      "doi-asserted-by": "crossref",
      "first-page": "149",
      "DOI": "10.1016/0021-9797(91)90043-8",
      "article-title": "Protein-surface interactions in the presence of polyethylene oxide",
      "volume": "142",
      "author": "Jeon",
      "year": "1991",
      "journal-title": "J Colloid Interface Sci"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib17",
      "doi-asserted-by": "crossref",
      "first-page": "657",
      "DOI": "10.1016/S1470-2045(06)70793-8",
      "article-title": "Emerging use of nanoparticles in diagnosis and treatment of breast cancer",
      "volume": "7",
      "author": "Yezhelyev",
      "year": "2006",
      "journal-title": "Lancet Oncol"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib18",
      "doi-asserted-by": "crossref",
      "first-page": "164",
      "DOI": "10.1016/S1053-4296(98)80042-8",
      "article-title": "Transvascular drug delivery in solid tumors",
      "volume": "8",
      "author": "Yuan",
      "year": "1998",
      "journal-title": "Semin Radiat Oncol"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib19",
      "doi-asserted-by": "crossref",
      "first-page": "5317",
      "DOI": "10.1158/0008-5472.CAN-04-3921",
      "article-title": "Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer",
      "volume": "65",
      "author": "Kukowska-Latallo",
      "year": "2005",
      "journal-title": "Cancer Res"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib20",
      "doi-asserted-by": "crossref",
      "first-page": "147",
      "DOI": "10.1016/S0169-409X(99)00062-9",
      "article-title": "Targeted drug delivery via the folate receptor",
      "volume": "41",
      "author": "Sudimack",
      "year": "2000",
      "journal-title": "Adv Drug Deliv Rev"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib21",
      "doi-asserted-by": "crossref",
      "first-page": "1",
      "DOI": "10.1016/S0142-9612(99)00125-8",
      "article-title": "Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkyl cyanoacrylate nanoparticles",
      "volume": "21",
      "author": "Soma",
      "year": "2000",
      "journal-title": "Biomaterials"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib22",
      "doi-asserted-by": "crossref",
      "first-page": "22",
      "DOI": "10.1016/j.nano.2004.11.009",
      "article-title": "Nanostructure-mediated drug delivery",
      "volume": "1",
      "author": "Hughes",
      "year": "2005",
      "journal-title": "Nanomed Nanotech Biol Med"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib23",
      "doi-asserted-by": "crossref",
      "first-page": "311",
      "DOI": "10.1096/fj.04-2747rev",
      "article-title": "Nanomedicine: Current status and future prospects",
      "volume": "19",
      "author": "Moghimi",
      "year": "2005",
      "journal-title": "FASEB J"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib24",
      "doi-asserted-by": "crossref",
      "first-page": "561",
      "DOI": "10.1038/380561a0",
      "article-title": "Doxorubicin in sterically stabilized liposomes",
      "volume": "380",
      "author": "Lasic",
      "year": "1996",
      "journal-title": "Nature"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib25",
      "doi-asserted-by": "crossref",
      "first-page": "1253",
      "DOI": "10.1126/science.7434025",
      "article-title": "pH-sensitive liposomes: Possible clinical implications",
      "volume": "210",
      "author": "Yalvin",
      "year": "1980",
      "journal-title": "Science"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib26",
      "first-page": "2186",
      "article-title": "Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes",
      "volume": "54",
      "author": "Huang",
      "year": "1994",
      "journal-title": "Cancer Res"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib27",
      "doi-asserted-by": "crossref",
      "first-page": "440",
      "DOI": "10.1093/annonc/mdh097",
      "article-title": "Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) vs. conventional doxorubicin for first-line treatment of metastatic breast cancer",
      "volume": "15",
      "author": "O\u2019Brien",
      "year": "2004",
      "journal-title": "Ann Oncol"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib28",
      "doi-asserted-by": "crossref",
      "first-page": "1128",
      "DOI": "10.1016/S0022-3565(24)38244-8",
      "article-title": "Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes",
      "volume": "289",
      "author": "Working",
      "year": "1999",
      "journal-title": "J Pharmacol Exp Ther"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib29",
      "first-page": "22",
      "article-title": "Stealth Liposomes",
      "author": "Lasic",
      "year": "1995"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib30",
      "doi-asserted-by": "crossref",
      "first-page": "3312",
      "DOI": "10.1200/JCO.2001.19.14.3312",
      "article-title": "Recurrent epithelial ovarian carcinoma: A randomized Phase III study of pegylated liposomal doxorubicin vs. topotecan",
      "volume": "19",
      "author": "Gordon",
      "year": "2001",
      "journal-title": "J Clin Oncol"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib31",
      "doi-asserted-by": "crossref",
      "first-page": "2445",
      "DOI": "10.1200/JCO.1998.16.7.2445",
      "article-title": "Pegylated-liposomal doxorubicin vs. doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma: Results of a randomized Phase III clinical trial",
      "volume": "16",
      "author": "Northfelt",
      "year": "1998",
      "journal-title": "J Clin Oncol"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib32",
      "doi-asserted-by": "crossref",
      "first-page": "683",
      "DOI": "10.1200/JCO.1998.16.2.683",
      "article-title": "Randomized comparative trial of pegylated liposomal doxorubicin vs. bleomycin and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma",
      "volume": "16",
      "author": "Stewart",
      "year": "1998",
      "journal-title": "J Clin Oncol"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib33",
      "doi-asserted-by": "crossref",
      "first-page": "691",
      "DOI": "10.1097/01.cad.0000167902.53039.5a",
      "article-title": "Liposomal encapsulated anti-cancer drugs",
      "volume": "16",
      "author": "Hofheinz",
      "year": "2005",
      "journal-title": "Anticancer Drugs"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib34",
      "doi-asserted-by": "crossref",
      "first-page": "2353",
      "DOI": "10.1200/JCO.1996.14.8.2353",
      "article-title": "Randomized Phase III trial of liposomal daunorubicin vs. doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi\u2019s sarcoma",
      "volume": "14",
      "author": "Gill",
      "year": "1996",
      "journal-title": "J Clin Oncol"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib35",
      "series-title": "San Antonio Breast Cancer Symposium",
      "article-title": "Increased endothelial transcytosis of nanoparticle albumin-bound paclitaxel (AB1-007) by endothelial gp60 receptors: A pathway inhibited by Taxol",
      "author": "Desai",
      "year": "2004"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib36",
      "doi-asserted-by": "crossref",
      "first-page": "2187",
      "DOI": "10.1046/j.1432-1327.2001.02107.x",
      "article-title": "High affinity binding of paclitaxel to human serum albumin",
      "volume": "268",
      "author": "Paal",
      "year": "2001",
      "journal-title": "Eur J Biochem"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib37",
      "doi-asserted-by": "crossref",
      "first-page": "61",
      "DOI": "10.1016/S0167-4838(99)00251-4",
      "article-title": "Interaction of taxol with human serum albumin",
      "volume": "1478",
      "author": "Purcell",
      "year": "2000",
      "journal-title": "Biochim Biophys Acta"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib38",
      "first-page": "1027",
      "article-title": "The differential expression of SPARC in esophageal squamous cell carcinoma",
      "volume": "17",
      "author": "Che",
      "year": "2006",
      "journal-title": "Int J Mol Med"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib39",
      "first-page": "5376",
      "article-title": "Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients",
      "volume": "63",
      "author": "Koukourakis",
      "year": "2003",
      "journal-title": "Cancer Res"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib40",
      "doi-asserted-by": "crossref",
      "first-page": "1317",
      "DOI": "10.1158/1078-0432.CCR-05-1634",
      "article-title": "Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel",
      "volume": "12",
      "author": "Desai",
      "year": "2006",
      "journal-title": "Clin Cancer Res"
    },
    {
      "year": "2005",
      "series-title": "Abraxane prescribing information",
      "key": "10.1016/j.urolonc.2007.03.015_bib41"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib42",
      "doi-asserted-by": "crossref",
      "first-page": "7794",
      "DOI": "10.1200/JCO.2005.04.937",
      "article-title": "Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer",
      "volume": "23",
      "author": "Gradishar",
      "year": "2005",
      "journal-title": "J Clin Oncol"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib43",
      "series-title": "San Antonio Breast Cancer Symposium",
      "article-title": "Weekly nanoparticle albumin paclitaxel (Abraxane) results in long term disease control in patients with taxane-refractory metastatic breast cancer",
      "author": "O\u2019Shaughnessy",
      "year": "2000"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib44",
      "doi-asserted-by": "crossref",
      "first-page": "1513",
      "DOI": "10.1056/NEJMoa041318",
      "article-title": "Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer",
      "volume": "351",
      "author": "Petrylak",
      "year": "2004",
      "journal-title": "N Engl J Med"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib45",
      "doi-asserted-by": "crossref",
      "first-page": "1502",
      "DOI": "10.1056/NEJMoa040720",
      "article-title": "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer",
      "volume": "351",
      "author": "Tannock",
      "year": "2004",
      "journal-title": "N Engl J Med"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib46",
      "doi-asserted-by": "crossref",
      "first-page": "6315",
      "DOI": "10.1073/pnas.0601755103",
      "article-title": "Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo",
      "volume": "103",
      "author": "Farokhzad",
      "year": "2006",
      "journal-title": "Proc Natl Acad Sci USA"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib47",
      "doi-asserted-by": "crossref",
      "first-page": "335",
      "DOI": "10.1002/ijc.20405",
      "article-title": "Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer",
      "volume": "112",
      "author": "Sahoo",
      "year": "2004",
      "journal-title": "Int J Cancer"
    },
    {
      "key": "10.1016/j.urolonc.2007.03.015_bib48",
      "doi-asserted-by": "crossref",
      "first-page": "243",
      "DOI": "10.2174/1567201054368002",
      "article-title": "Folate-linked lipid-based nanoparticle for targeted gene delivery",
      "volume": "2",
      "author": "Hattori",
      "year": "2005",
      "journal-title": "Curr Drug Deliv"
    }
  ],
  "container-title": "Urologic Oncology: Seminars and Original Investigations",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://api.elsevier.com/content/article/PII:S1078143907000907?httpAccept=text/xml",
      "content-type": "text/xml",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://api.elsevier.com/content/article/PII:S1078143907000907?httpAccept=text/plain",
      "content-type": "text/plain",
      "content-version": "vor",
      "intended-application": "text-mining"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2025,
        1,
        25
      ]
    ],
    "date-time": "2025-01-25T14:25:57Z",
    "timestamp": 1737815157000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://linkinghub.elsevier.com/retrieve/pii/S1078143907000907"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2008,
        1
      ]
    ]
  },
  "references-count": 48,
  "journal-issue": {
    "issue": "1",
    "published-print": {
      "date-parts": [
        [
          2008,
          1
        ]
      ]
    }
  },
  "alternative-id": [
    "S1078143907000907"
  ],
  "URL": "http://dx.doi.org/10.1016/j.urolonc.2007.03.015",
  "relation": {},
  "ISSN": [
    "1078-1439"
  ],
  "subject": [],
  "container-title-short": "Urologic Oncology: Seminars and Original Investigations",
  "published": {
    "date-parts": [
      [
        2008,
        1
      ]
    ]
  }
}